Dr Jacqueline C. Barrientos, MD

ACTIVITÉ ACCRÉDITÉE
Maintien du certificat du Collège royal des médecins et
chirurgiens du Canada
Dr Jacqueline C. Barrientos, MD
Hematologist, New Hyde Park
Assistant Professor, Hofstra Northwell School of Medicine
New York
“The Treatment of Relapsed/Refractory
CLL with Novel Agents”
Mercredi, 20 avril 2016
SITE GLEN
Salle D.02.1312
8:30 à 9:30
Visioconférence: [email protected]
Hôpital Charles-Le Moyne
Salle HN-106
12:00 à 13:00
Visioconférence: [email protected]
Hôpital Notre-Dame
Amphithéâtre Deschamps
17:00 à 18:00
En direct sur le Web! www.vpsolution.tv/ppio
Problèmes/Questions: 514 813-4510
(Salle I-1176-2)
Jeudi, 21 avril 2016
Hôpital du Sacré-Cœur de Montréal
Salle C-5175
8:00 à 9:00
Hôpital général juif
Salle E-711
12:30 à 13:30
Visioconférence: [email protected]
Objectifs d’apprentissage
• Recognize the role of novel CLL agents in the treatment of relapsed/refractory Chronic Lymphocytic Leukemia (CLL)
• Determine how and when to use novel agents in the treatment of CLL
• Explore the clinical experience with novel agents in relapsed/refractory CLL treatment through the review of
patients cases
Cette activité est accréditée pour 1 crédit par le bureau de Développement professionnel continu. Le bureau de DPC de la Faculté de médecine de
l’Université McGill est autorisé par le Comité d’agrément pour l’éducation médicale continue (CAÉMC). Cette activité est une activité de formation collective
agréée, aux termes de la section 1 du programme de Maintien du certificat du Collège royal des médecins et chirurgiens du Canada. En vertu d'une entente
conclue entre le Collège royal des médecins et chirurgiens du Canada et l'American Medical Association, les médecins peuvent convertir les crédits obtenus
au titre du programme de MDC du Collège royal en crédits de catégorie 1 de l'AMA PRAMC. Vous trouverez l'information sur le processus de conversion des
crédits du programme de MDC du Collège royal en crédits de l'AMA à l’adresse www.amaassn.org/go/internationalcme. Chaque médecin doit demander des
crédits seulement pour le nombre d’heures où il/elle a participé à l’activité de formation. Pour plus d’information, visitez notre site Internet au:
http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers_fr.asp
Ce programme bénéficie d’une subvention éducative de :
Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Gilead, Janssen, Lilly Oncologie, Lundbeck, Merck,
Novartis, Pfizer, Roche
EVENT ACCREDITED
Maintenance of Certification program of the Royal College
of Physicians and Surgeons of Canada
Dr Jacqueline C. Barrientos, MD
Hematologist, New Hyde Park
Assistant Professor, Hofstra Northwell School of Medicine
New York
“The Treatment of Relapsed/Refractory
CLL with Novel Agents”
Wednesday, April 20, 2016
GLEN Site
Room D 02.1312
8:30 to 9:30
Videoconference: [email protected]
Hôpital Charles-Le Moyne
Salle HN-106
12:00 to 13:00
Videoconference: [email protected]
Hôpital Notre-Dame
Amphithéâtre Deschamps
17:00 to 18:00
Live on the Web! www.vpsolution.tv/vspo
Problems/Questions: 514 813-4510
(Room I-1176-2)
Thursday, April 21, 2016
Hôpital du Sacré-Cœur de Montréal
Room C-5175
8:00 to 9:00
Jewish Gereral Hospital
Room E-711
12:30 to 13:30
Videoconference: [email protected]
Learning Objectives
• Recognize the role of novel CLL agents in the treatment of relapsed/refractory Chronic Lymphocytic Leukemia (CLL)
• Determine how and when to use novel agents in the treatment of CLL
• Explore the clinical experience with novel agents in relapsed/refractory CLL treatment through the review of
patients cases
This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University
is fully accredited by the Committee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as
defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal
College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA
Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at
www.amaassn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For
more information, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers.asp
This program has received an educational grant from :
Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Gilead, Janssen, Lilly Oncology, Lundbeck, Merck,
Novartis, Pfizer, Roche